Rifabutin Is Bactericidal against Intracellular and Extracellular Forms of Mycobacterium abscessus.

ABSTRACT: Mycobacterium abscessus is increasingly recognized as an emerging opportunistic pathogen causing severe lung diseases. As it is intrinsically resistant to most conventional antibiotics, there is an unmet medical need for effective treatments. Repurposing of clinically validated pharmaceuticals represents an attractive option for the development of chemotherapeutic alternatives against M. abscessus infections. In this context, rifabutin (RFB) has been shown to be active against M. abscessus and has raised renewed interest in using rifamycins for the treatment of M. abscessus pulmonary diseases. Here, we compared the in vitro and in vivo activity of RFB against the smooth and rough variants of M. abscessus, differing in their susceptibility profiles to several drugs and physiopathologial cha

SUBMITTER: Johansen MD 

PROVIDER: S-EPMC7577168 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature